

DATE:	2022 July 25
TO:	All physicians, clinicians, and laboratory professionals
FROM:	Alberta Precision Laboratories (APL) North Sector, University of Alberta Hospital (UAH)
RE:	Updates to the Calcium Infusion and Glucagon Stimulation Panels in Epic

PLEASE POST OR DISTRIBUTE AS WIDELY AS APPROPRIATE

Key Message

- Effective **Thursday July 28, 2022**, there will be updates to two stimulation panels in Epic:
 - (1) The Calcium Infusion Panel will be inactivated with no replacement and will not be orderable at this time.
 - (2) Addition of glucose time points to the Glucagon Stimulation Panel therapy protocol.

Background

- The Calcium Infusion Panel is used in diagnosis of medullary thyroid carcinoma, but no longer commonly used and rarely ordered in Alberta.
- The Glucagon Stimulation Panel is used in diagnosis of growth hormone deficiency or used when the Insulin Tolerance Test is contraindicated. It involves measurement of growth hormone, cortisol, and glucose at different time points. Addition of glucose time points will improve coordination and interpretation of timed samples in Epic.
- These tests are primarily ordered and interpreted by endocrinology specialists in Edmonton and Calgary.
- Endocrinology in Edmonton and Calgary were consulted and support these changes.

Action Required

- Be aware of the following changes to dynamic testing in Epic: inactivation of the Calcium Infusion Panel and addition of glucose time points to the Glucagon Stimulation Panel therapy plan.
- There are no changes to test ordering.
- The Calcium Infusion Panel can still be performed on an ad hoc basis by contacting Client Response at UAH to coordinate ordering and sample collection (780-407-7484).

Questions/Concerns

- Dr. Josh Raizman, Clinical Biochemist, APL, North Sector, 780-718-2402 or josh.raizman@aplabs.ca

Approved by

- Dr. Kareena Schnabl, Section Chief, Clinical Biochemistry, North Sector, APL
- Dr. Michael Mengel, Medical Director, North Sector, AP